CBD's effectiveness for alcohol use disorder remains uncertain

A recent updated review of clinical studies found that evidence supporting the use of cannabidiol (CBD) as a treatment for alcohol use disorder (AUD) remains inconclusive. The review, which examined a range of pre‑clinical and early‑phase human trials, concluded that the current data do not demonstrate a clear therapeutic benefit of CBD for reducing alcohol consumption or preventing relapse.

The analysis highlighted several limitations in the existing research, including small sample sizes, short follow‑up periods, and heterogeneous study designs. While some trials reported modest reductions in craving or withdrawal symptoms, the results were inconsistent and often not statistically significant. The authors noted that methodological differences and the lack of standardized dosing protocols make it difficult to compare outcomes across studies.

Given these uncertainties, the review’s authors emphasize the need for larger, well‑controlled randomized trials to determine whether CBD can safely and effectively address AUD. Continued investigation into optimal dosing, long‑term efficacy, and potential interactions with other treatments will be essential before CBD can be recommended as a standard therapeutic option.